1
1
If you were seeking treatment for cancer or consultation on current treatment, would you consult anyone with the specialties listed? Not if you're concerned about your health. Cancer is not what these doctors treat. Dr. Zurrbier's point was so obvious, she seemed amazed that this kind of finding could even occur. So should we.
WUSA's did an on-the-spot review of task force member affiliations. They came up with three members tied to HMO's or health insurance companies. Dr. George Isham, MD is the Chief Health Officer for a major health care provider, Health Partners. Dr. David Grossman, MD, is an investigator a research division of the Group Health Cooperative health care network in the Seattle area. Dr. J. Sanford Schwartz, MD, is the past executive director of the Leonard Davis Institute of Health Economics at the University of Pennsylvania. He's also on the Blue Shield Medical Advisory Panel.
There are three other affiliations that deserve note.
Task force Chairman, Bruce Nedrow Calonge, MD, is a Colorado physician who is the Chairman of the Colorado Foundation for Medical Care, a major advisor on "quality improvement" in care for the state and other health care organizations. Dr. Pettiti, who said the recommendations would have no influence on insurance coverage, is a health policy and medical advisor for Kaiser Permanente of Southern California. Joy Melnikow, MD is the associate medical advisers for Healthwise, a medical knowledgebase company serving health providers, insurance companies, and government entities. The firm also provides software for patient information.
Thanks to the incisive questioning of NPR syndicated radio host Diane Rehm and the quick and clear response of cancer specialist, Dr. Zurrbier on WUSA, the issue hit the public airwaves and was quickly resolved with the rapid response of HHS Secretary Sebelius.
Now it's time to find out how this HHS research organization could impanel a group of experts to recommend cancer treatment protocols when none of the physicians on the panel were oncologists and none had any identified clinical experience treating cancer. It's also a good time for those on the task force to examine why they chose to issue this guideline without cancer researchers and clinicians on the committee?
Why were the deficiencies in this process, so obvious to us, too difficult for the HHS administrators to grasp?
END
This article may be reproduced in whole or in part with attribution of authorship and a link to this article.
1 | 2
